Carney EF .2015 .Epidemiology: Global Burden of Disease Study 2013 reports that disability caused by CKD is increasing worldwide. Nature Rev Nephrol, 11 : 446-9.
Richette P,Doherty M,Pascual E,Barskova V,Becce F,Castañeda-Sanabria J .2017 .2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis, 76 : 29-42.
Eleftheriadis T,Golphinopoulos S,Pissas G,Stefanidis I. .2017 .Asymptomatic hyperuricemia and chronic kidney disease: Narrative review of a treatment controversial. J Adv Res, 8 : 555-60.
Zhu Y,Pandya BJ,Choi HK .2011 .Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum, 63 : 3136-41.
Nan H,Qiao Q,Dong Y,Gao W,Tang B,Qian R .2006 .The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China. J Rheumatol, 33 : 1346-50.
Rincon-Choles H,Jolly SE,Arrigain S,Konig V,Schold JD,Nakhoul G .2017 .. Impact of Uric Acid Levels on Kidney Disease Progression. Am J Nephrol, 46 : 315-22.
Tsai CW,Lin SY,Kuo CC,Huang CC .2017 .Serum Uric Acid and Progression of Kidney Disease: A Longitudinal Analysis and Mini-Review. PLoS One, 12 : e0170393.
Kumagai T,Ota T,Tamura Y,Chang WX,Shibata S,Uchida S. .2017 .Time to target uric acid to retard CKD progression. Clin Exp Nephrol, 21 : 182-92.
Sampson AL,Singer RF,Walters GD .2017 .Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease. Cochrane Database Syst Rev, 10 : CD009460.
Pisano A,Cernaro V,Gembillo G,D'Arrigo G,Buemi M,Bolignano D. Xanthine M .2017 .Oxidase Inhibitors for Improving Renal Function in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis. Int J Mol Sci, 18 : 2283.
Matsuo H,Ishikawa E,Machida H,Mizutani Y,Tanoue A,Ohnishi T .2020 .Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia. Clin Exp Nephrol, 24 : 307-13.
Kamel B,Graham GG,Williams KM,Pile KD,Day RO .2017 .. Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat. Clin Pharmacokinet, 56 : 459-75.
Kimura K,Hosoya T,Uchida S,Inaba M,Makino H,Maruyama S .2018 .Febuxostat Therapy for Patients with Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. Am J Kidney Dis, 72 : 798-810.
Liu X,Wang H,Ma R,Shao L,Zhang W,Jiang W .2019 .The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3- 5. Clin Exp Nephrol, 23 : 362-70.
Gunawardhana L,Becker MA,Whelton A,Hunt B,Castillo M .2018 .Saag K. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebocontrolled study. Arthritis Res Ther, 20 : 99.
Rincon-Choles H,Jolly SE,Arrigain S,Konig V,Schold JD,Nakhoul G .2017 .. Impact of Uric Acid Levels on Kidney Disease Progression. Am J Nephrol, 46 : 315-22.
Xia X,Luo Q,Li B,Lin Z,Yu X,Huang F .2016 .Serum uric acid and mortality in chronic kidney disease: A systematic review and meta-analysis. Metabolism, 65 : 1326-41.
Jackson RL,Hunt B,MacDonald PA B .2012 .The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. BMC Geriatr, 12 : 11-6.
Peng YL,Tain YL,Lee CT,Yang YH,Huang YB,Wen YH .2020 .Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with chronic kidney disease. Sci Rep, 10 : 1-1.
Kojima S,Matsui K,Hiramitsu S,Hisatome I,Waki M,Uchiyama K .2019 .Febuxostat for Cerebral and CaRdiorenovascular Events Prevention Study. Eur Heart J, 40 : 1778-86.
Shibagaki Y,Ohno I,Hosoya T,Kimura K .2014 .Safety, efficacy and renal effect of febuxostat in patients with moderate-to-severe kidney dysfunction. Hypertension Res, 37 : 919-25.
Lin TC,Hung LY,Chen YC,Lo WC,Lin CH,Tam KW .2019 .Effects of febuxostat on renal function in patients with chronic kidney disease: A systematic review and meta-analysis. Medicine, 98 : e16311.
Kaewput W,Thongprayoon C,Rangsin R,Ruangkanchanasetr P,Bathini T,Mao MA .2019 .Association between serum uric acid and chronic kidney disease in patients with hypertension: A multicenter nationwide cross-sectional study. J Evid Based Med, 12 : 235-42.